Daratumumab (Dara), Cyclophosphamide, Thalidomide and Dexamethasone for Transplant Eligible Newly Diagnosed Multiple Myeloma (TE NDMM) Patients: Response Rate Impacts on PFS

被引：0
|
作者：
Crusoe, Edvan De Queiroz [1 ,2 ,3 ]
Leal, Joanna [4 ]
Santos, Juliana Andrade [5 ,6 ]
de Melo Santos, Herbert Henrique [7 ]
Santos, Allan de Souza [7 ]
Lucas, Larissa Ferreira [6 ]
Almeida, Alessandro de M. [8 ,9 ]
Chaves, Marcos [10 ]
Dutra, Daniela Dourado [5 ]
Hungria, Vania T. M. [11 ,12 ]
Salvino, Marco Aurelio [2 ,13 ]
Arruda, Maria da Gloria B. [6 ]
机构：
[1] Univ Fed Bahia Hosp Univ, Rua Dra Doutro Vianna S-n, Salvador, BA, Brazil
[2] Hosp Univ Prof Edgard Santos Fed Univ Bahia HUPES, Salvador, BA, Brazil
[3] Clin CEHON Rede Dor Oncol, Hematol Dept Dor Oncol, Salvador, BA, Brazil
[4] Hematol Rede Dor Oncol, Hematol, Salvador, BA, Brazil
[5] Univ Fed Bahia, Salvador, BA, Brazil
[6] CLin CEHON Rede Dor Oncol, Hematol, Salvador, BA, Brazil
[7] Univ Fed Bahia, Immunol Mol & Cytometry Lab ICS, Salvador, BA, Brazil
[8] Univ Fed Bahia, Stem Cell Transplant Unit, Salvador, BA, Brazil
[9] Rede Dor Oncol, Hematol & Bone Marrow Unit, Salvador, BA, Brazil
[10] Fed Univ Bahia Hematol & Hemotheraphy, Salvador, BA, Brazil
[11] Santa Casa Med Sch, Hematol, Sao Paulo, Brazil
[12] Clin Sao Germano, Dept Hematol & Oncol, Sao Paulo, Brazil
[13] Rede Dor Oncol, Hematol & Bone Marrow Transplantat UNIT, Salvador, BA, Brazil
来源：
BLOOD | 2022年 / 140卷
关键词：
D O I：
10.1182/blood-2022-164866
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：7699 / 7700
页数：2
相关论文
共 50 条
  • [1] Progression Free Survival (PFS) Analysis of Daratumumab (Dara), Cyclophosphamide, Thalidomide and Dexamethasone: A Quadruplet Intensified Treatment for Transplant Eligible Newly Diagnosed Multiple Myeloma (TE NDMM) Patients
    Crusoe, Edvan De Queiroz
    Leal, Joanna
    Salvino, Marco Aurelio
    Lucas, Larissa Ferreira
    Santos, Juliana Andrade
    Santos, Herbert Henrique de Melo
    Almeida, Alessandro de M.
    Santos, Allan de souza
    Chaves, Marcos
    Santos, Mariane Melo
    Silva, Sarah Queiroz
    Vieira, Lucas de Oliveira
    Fonseca, Cleverson Alves
    Adorno, Elisangela
    Hungria, Vania
    Arruda, Maria da Gloria B.
    BLOOD, 2021, 138
  • [2] Daratumumab (Dara), Cyclophosphamide, Thalidomide and Dexamethasone: a quadruplet intensified treatment for transplant eligible newly diagnosed Multiple Myeloma (TE NDMM) patients final results
    Crusoe, Edvan
    Santos, Juliana
    Leal, JOanna
    Santos, Herbert
    Santos, Allan
    Almeida, Alessandro
    Santos, Mariane
    Lucas, Larissa
    Queiroz, Sarah
    Fonseca, Cleverson
    Adorno, Elisangela
    Vieira, Lucas
    Hungria, Vania
    Salvino, Marco
    Arruda, Maria da Gloria
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S130 - S130
  • [3] Preliminary Results of Daratumumab, Cyclophosphamide, Thalidomide and Dexamethasone: A Quadruplet Intensified Treatment for Newly Diagnosed Multiple Myeloma (NDMM) Transplant Eligible (TE) Patients
    Crusoe, Edvan De Queiroz
    Salvino, Marco Aurelio
    Silva, Sarah Queiroz
    Santos, Herbert Henrique de Melo
    Santos, Allan de Souza
    Almeida, Alessandro de M.
    Vieira, Lucas de Oliveira
    Fonseca, Cleverson Alves
    Lucas, Larissa Ferreira
    Leal, Joanna
    Santos, Mariane Melo
    Santos, Juliana Andrade
    Adorno, Elisangela
    Hungria, Vania T. M.
    Arruda, Maria da Gloria B.
    BLOOD, 2020, 136
  • [4] Immune Profiling Evaluation of Newly Diagnose Multiple Myeloma (NDMM) Transplant Eligible (TE) Patients Treated with Daratumumab, Cyclophosphamide, Thalidomide and Dexamethasone. Preliminary Results
    Santos, Allan de Souza
    Santos, Herbert Henrique de Melo
    Salvino, Marco Aurelio
    Silva, Sarah Queiroz
    Lucas, Larissa Ferreira
    Almeida, Alessandro de M.
    Santos, Mariane Melo
    Santos, Juliana Andrade
    Hungria, Vania T. M.
    Arruda, Maria da Gloria B.
    Torres, Alex
    Crusoe, Edvan De Queiroz
    BLOOD, 2020, 136
  • [5] Bortezomib, lenalidomide, and dexamethasone (VRd) daratumumab (DARA) in patients (pts) with transplant -eligible (TE) newly diagnosed multiple myeloma (NDMM): A multicenter, randomized, phase Ill study (PERSEUS).
    Sonneveld, Pieter
    Broijl, Annemiek
    Gay, Francesca
    Boccadoro, Mario
    Einsele, Hermann
    Blade, Joan
    Dimopoulos, Meletios A.
    Delforge, Michel
    Spencer, Andrew
    Hajek, Roman
    Schjesvold, Fredrik
    Lonergan, Sarah
    Smith, Elena
    Carson, Robin L.
    Crist, Wendy
    Garvin, Wendy S.
    Vermeulen, Jessica
    Moreau, Philippe
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [6] Effects of Daratumumab(dara), Cyclophosphamide (C), Thalidomide (T) and Dexamethasone (D) Combination on Lymphocyte Populations of Transplant Eligible Newly Diagnose Multiple Myeloma Patients
    Santos, Allan
    Santos, Herbert
    Leal, Joanna
    Santos, Juliana
    Salvino, Marco
    Lucas, Larissa
    Santos, Mariane
    Hungria, Vania T. M.
    Torres, Alex
    Crusoe, Edvan de Queiroz
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S178 - S179
  • [7] Preliminary results of Daratumumab, cyclophosphamide, thalidomide and dexamethasone- A quadruplet intensified treatment to newly diagnosed multiple myeloma transplant eligible patients
    Crusoe, Edvan de Queiroz
    Santos, Juliana
    Santos, Allan
    Santos, Mariane Melo
    Salvino, Marco Aurelio
    Adorno, Elisangela
    Moura, Alessandro
    Fonseca, Cleverson Alves
    Queiroz, Sarah
    Bomfim, Maria da Gloria
    Nicanor, Jamile
    Santos, Herbert Henrique
    Hungria, Vania
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E145 - E146
  • [8] Stem Cell Mobilization Characteristics for Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma (NDMM) Treated with Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab (KRd-Dara)
    Bhutani, Manisha
    Robinson, Myra
    Atrash, Shebli
    Watts, Nicole
    Paul, Barry
    Chhabra, Saurabh
    Korde, Neha
    Begic, Xhevahire
    Foureau, David M.
    Chung, David J.
    Pineda-Roman, Mauricio
    Koya, Brinda
    Varga, Cindy
    Ai, Jing
    Daniels, Natonya
    Norek, Sarah
    Sutton, Sara A.
    Anderson, Michelle B.
    Jewell, Ashley N.
    Eldridge, Paul W.
    Acampora, Donna
    Symanowski, James T.
    Costa, Luciano J.
    Usmani, Saad
    Voorhees, Peter M.
    BLOOD, 2022, 140 : 4393 - 4395
  • [9] Daratumumab (DARA) plus Bortezomib/Thalidomide/Dexamethasone (D-VTd) and DARA Maintenance in Transplant-eligible Newly Diagnosed Multiple Myeloma (NDMM): CASSIOPEIA Minimal Residual Disease (MRD) Update
    Corre, Jill
    Vincent, Laure
    Moreau, Philippe
    Hebraud, Benjamin
    Hulin, Cyrille
    Bene, Marie
    Broijl, Annemiek
    Caillot, Denis
    Delforge, Michel
    Dejoie, Thomas
    Facon, Thierry
    Lambert, Jerome
    Leleu, Xavier
    Macro, Margaret
    Perrot, Aurore
    Zweegman, Sonja
    Hua, Winnie
    Krevvata, Maria
    Vanquickelberghe, Veronique
    Tuozzo, Alba
    Rowe, Melissa
    Carson, Robin
    Wuilleme, Soraya
    Avet-Loiseau, Herve
    Sonneveld, Pieter
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S29 - S30
  • [10] Daratumumab (DARA) plus lenalidomide/bortezomib/dexamethasone (RVd) in Black patients with transplant-eligible newly diagnosed multiple myeloma (NDMM): an updated subgroup analysis of GRIFFIN
    Nooka, Ajay
    Kaufman, Jonathan
    Rodriguez, Cesar
    Jakubowiak, Andrzej
    Efebera, Yvonne
    Reeves, Brandi
    Wildes, Tanya
    Holstein, Sarah
    Anderson, Larry
    Badros, Ashraf
    Shune, Leyla
    Chari, Ajai
    Pei, Huiling
    Cortoos, Annelore
    Patel, Sharmila
    Lin, Thomas
    Usmani, Saad
    Richardson, Paul
    Voorhees, Peter
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S155 - S156
12345